Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$52.80, Keeps at Buy

03:24 AM EDT, 07/16/2024 (MT Newswires) -- Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$52.80, Keeps at BuyPrice (HKD): $39.05, Change: $+0.50, Percent Change: +1.30%

MT Newswires03:24 ET

Hong Kong stocks surge | Akeso (09926) rose more than 5%, the Phase III study of Calquence in the first-line treatment of advanced cervical cancer met the dual primary endpoints of PFS and OS.

Akeso (09926) rose by more than 5%, as of press time, it rose by 5.19% to HKD 40.55, with a turnover of HKD 0.168 billion.

Zhitong Finance22:58 ET

Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.

Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.

Zhitong Finance20:35 ET

HK stocks fluctuate | Akeso (09926) is up nearly 5%, and the biggest uncertainty of its Yiviva MAb has been resolved, it is expected to be listed overseas in the future.

Akeso (09926) is currently up nearly 5%, as of press time, up 4.83% at HKD 40.15, with a turnover of HKD 0.224 billion.

Zhitong FinanceJul 12 02:07 ET

[Brokerage Focus] Guolian Securities maintains its "buy" rating on Akeso Bio (09926) and suggests potential approval for two self-immune and lipid-lowering drugs outside the cancer field.

Guolian Securities published a research report, stating that Akeso (09926) is the first domestic enterprise to commercialize dual-antibody products. It has established a layout for tumor-targeting dual antibodies, immune evasion, and lipid-lowering drugs. Established in 2012, the company now has over a hundred varieties of drugs, including Cardunali and Pemigatinib, of which the cervical cancer drug Cardunali achieved annual sales of over 1 billion yuan; the lung cancer drug Ivosidenib is currently in development with an upfront payment of 0.5 billion yuan, and is expected to be released domestically and internationally by 2024; with two immune evasion and lipid-lowering drugs expected to be approved for non-tumor markets by 2024. The bank predicts that the company will reach

金吾財訊Jul 9 03:08 ET

HuaFu Securities: First time issuing a "buy" rating for Akeso (09926), target price of HK$55.85.

Huafu Securities predicts that Akeso's (09926) revenue will be 2.57 billion yuan, 3.98 billion yuan, and 6.15 billion yuan from 2024 to 2026, respectively.

Zhitong FinanceJul 8 22:06 ET